Animal StudyPubMed ID: 20452065·2010

Semax Reduces Brain Inflammation and Microglial Activation After Stroke

Gusev EI, Skvortsova VI, Kamayev YA, et al.

Journal of Neuroimmunology, 2010

Key finding

Semax reduced infarct-associated microglial activation by 58%, decreased IL-6 levels 67%, and decreased TNF-alpha 52%.

Summary

Study examining semax effects on post-stroke neuroinflammation, microglial activation (Iba1+), and pro-inflammatory cytokine production.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaxL3

A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.

More research on Semax

Semax Restores Behavioral Performance and Spatial Memory in Alzheimer Disease Model Mice

Neurobiology of Aging · 2011 · Animal Study

Semax Effects on BDNF, NGF, and GDNF: Neurotrophic Factor Signaling in Recovery From Neuronal Injury

Journal of Molecular Neuroscience · 2010 · Animal Study

Semax Improves Optic Nerve Function and Visual Acuity in Patients with Optic Neuropathy

Journal of the Neurological Sciences · 2009 · Human RCT

Semax Effects on Immune Function: Enhanced T-Cell Proliferation and Altered Cytokine Profile

International Immunology · 2009 · Human Pilot

Nasal Peptide Semax: Tolerability Profile and Safety Data Across Multiple Clinical Studies

Drug Safety · 2009 · Review